Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the 34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ online CME activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Astellas, AstraZeneca, Celgene Corporation, Genentech, Genomic Health, Inc., Eisai, Inc., Incyte, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., and Pfizer.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™

Release Date: May 25, 2017
Expiration Date: May 25, 2018
Media: Internet - based

Activity Overview

Strategies for achieving the best possible outcomes for patients with breast cancer are prone to rapid change because of the pace at which advances in patient care across the cancer care continuum emerge. The Annual Miami Breast Cancer Conference® brings together breast cancer specialists to highlight the state of the art in multidisciplinary patient care. This year’s conference was no exception, with an agenda that featured clinical updates in local, regional, and systemic therapies; timely practice management and policy concerns; exploration of clinical controversies; patient-centered care (eg, psychosocial concerns and pain); and much more.

This online CME/CE-certified educational activity based on content presented at the Miami Breast Cancer Conference® consists of a series of interviews with Elizabeth Mittendorf, MD, PhD, and Debu Tripathy, MD, during which they discuss their approaches toward clinical cases and discuss other topics important to the practicing community clinician. Specifically, these renowned experts review current and emerging evidence on neoadjuvant therapy and immunotherapy for breast cancer, and offer practical guidance where appropriate.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Astellas, AstraZeneca, Celgene Corporation, Genentech, Genomic Health, Inc., Eisai, Inc., Incyte, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., and Pfizer.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Table of Contents

  • Neoadjuvant Therapy for Early-Stage, HER2-Positive Breast Cancer
    Debu Tripathy, MD
  • Immunotherapy in Breast Cancer
    Elizabeth Mittendorf, MD, PhD

 

Instructions For This Activity & Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on the request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Discuss clinical trial evidence that allows for the personalization of care in the management of early and advanced forms of breast cancer
  2. Assess current and evolving roles for prognostic and predictive biomarkers to stratify risk and inform clinical decision making in the management of breast cancer
  3. Examine recent clinical trial results concerning the use of novel breast cancer treatment strategies, and place them in the clinical context of evolving treatment paradigms in the field

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Faculty, Staff, and Planners' Disclosures

Faculty

Elizabeth Mittendorf, MD, PhD
Associate Professor and Deputy Chair for Research
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Other Disclosures: Galena Biopharma, Antigen Express, Genentech, AstraZeneca, EMD-Serono I do not personally receive funding, but my institution receives funding to support the conduct of clinical trials investigating vaccines owned by these companies.

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Research/Grant Support: Novartis; Consultant: Nektar, Novartis, Puma Biotechnology 

The staff of Physicians' Education Resource®, LLC, has no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Tripathy, during which he discussed:

  • His approach toward neoadjuvant therapy and follow-up for a 57-year-old female who was diagnosed with a grade II infiltrating ductal, HER2-positive breast cancer (clinical size = 3.8 cm).
  • Key components of neoadjuvant therapy response evaluation, including examination at every cycle of chemotherapy to detect progression and pathologic assessment at the time of surgery (eg, with residual cancer burden calculator)
  • Factors that influence degree of response to neoadjuvant therapy and how it translates into conversion from mastectomy to breast-conserving surgery eligibility, including tumor location, body type, size of breast, and patient preference
  • His perspective on data showing increased rates of pathologic complete response (pCR), but not survival, when lapatinib was added to neoadjuvant trastuzumab chemotherapy
  • Clinical questions being addressed by the KATHERINE trial of adding T-DM1 to adjuvant therapy to reduce risk of recurrence for patients who did not achieve pCR after standard neoadjuvant therapy

2 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Her approach toward discussing the status of immunotherapy with a 47-year-old female patient with metastatic, triple-negative breast cancer, who has no family history of breast or ovarian cancer and no evidence of deleterious mutations by breast cancer susceptibility gene panel testing
  • Recent data on the immunogenicity of breast cancer that provide rationale for the use of immunotherapy
  • Strategies being investigated to augment the immunogenicity/T-cell infiltrate in breast cancer

3 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Data from phase I trials of checkpoint inhibitor therapy for advanced, triple-negative breast cancer
  • How outcomes observed in trials of checkpoint inhibitors for breast cancer compare with those observed for other solid tumor types
  • Progress made toward identifying patients with breast cancer who are most likely to benefit from checkpoint inhibitor therapy
  • Rationale for using checkpoint inhibition in combination with other therapeutics






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By